



















| Test | | Lipoprotein Particle Numbers (nmol/L) * | Patient Results | Reference Value |
|---------------------|--------|--|-----------------|-----------------|
| VLDL Particles | nmol/L |  | 33 | <85 |
| Total LDL Particles | nmol/L |  | 735 | <900 |
| Total HDL Particles | nmol/L |  | 7811 | >7000 |
| Non-HDL Particles | nmol/L |  | 768 | <1000 |
| Remnant Lipoprotein | nmol/L |  | 93 | <150 |
| Dense LDL III | nmol/L |  | 237 | <300 |
| Dense LDL IV | nmol/L |  | 128 | <100 |
| Buoyant HDL 2b | nmol/L |  | 3067 | >1500 |

| Test | | Lipid Panel (mg/dL) | Patient Results | Reference Value |
|---------------------|-------|--|-----------------|-----------------|
| Cholesterol | mg/dL |  | 172 | <200 |
| Triglycerides | mg/dL |  | 73 | 30 - 150 |
| HDL | mg/dL |  | 72 | >40 |
| LDL | mg/dL |  | 91 | 40 - 130 |
| Non-HDL Cholesterol | mg/dL |  | 100 | <160 |

| Test | | Vascular Inflammation and Biomarkers | Patient Results | Reference Value |
|-------------------|--------|--|-----------------|-----------------|
| CRP-hs | mg/L |  | 1.75 | <3.00 |
| Lipoprotein(a) | mg/dL |  | 62.7 | 6.0 - 29.9 |
| Apolipoprotein A1 | mg/dL |  | 195 | > 115 |
| Apolipoprotein B | mg/dL |  | 82 | 40 - 100 |
| Homocysteine | μmol/L |  | 5.5 | <11.0 |

CardioMetabolic Risk Assessment

LOW

Reference Value:

LOW

The CardioMetabolic Risk Assessment is an indication of your risk for developing cardiovascular disease, including stroke and diabetes. It is a composite value derived from laboratory test results and may not capture all of the individual risk factors for a particular patient. Additional elements that can impact risk that are not included are weight, blood pressure (hypertension), smoking, inflammation, medical history and family history. The risk score is provided to supplement, not supplant, the clinical utility of individual biomarkers and other clinical indications. The CardioMetabolic Risk Assessment is not intended to provide a single indicator of risk. Treatment decisions should be based on the totality of available information.

* This test was developed and its performance characteristics determined by SpectraCell Laboratories. SpectraCell is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity laboratory testing. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.